NCT02773030 · OUTCOME

Very Good Partial Response Rate (ORR) in Cohort J1 and Cohort K

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma · Source last updated 2026-03-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of Participants
Interval / dispersion: 95% Confidence Interval
Time frame: On Average of (Cohort J: 86.21, Cohort K: 56.29) Weeks

What was measured

The very good partial response or better (≥ VGPR) rate is defined as the proportion of subjects with best response of VGPR or better during the trial without administration of myeloma therapy other than study treatment. The ≥ VGPR rate with 95% confidence interval (CI) together with the proportions in each response category based on the IMWG Uniform Response Criteria.

Analysis population: Safety Population in Cohort J1 and Cohort K

Groups in this outcome

Cohort A: Treatment 1

CC220 0.30mg

Cohort A: Treatment 2

CC220 0.45mg

Cohort A: Treatment 3

CC220 0.60mg

Cohort A: Treatment 4

CC220 0.75mg

Cohort A: Treatment 5

CC220 0.90mg

Cohort A: Treatment 6

CC220 1.0mg

Cohort B: Treatment 1

CC220 0.30mg + DEX

Cohort B: Treatment 2

CC220 0.45mg + DEX

Cohort B: Treatment 3

CC220 0.60mg + DEX

Cohort B: Treatment 4

CC220 0.75mg + DEX

Cohort B: Treatment 5

CC220 0.90mg + DEX

Cohort B: Treatment 6

CC220 1.0mg + DEX

Cohort B: Treatment 7

CC220 1.1mg + DEX

Cohort B: Treatment 8

CC220 1.2mg + DEX

Cohort B: Treatment 9

CC220 1.3.mg + DEX

Cohort B: Treatment 10

CC220 1.6mg + DEX

Cohort D: Treatment 1

CC220 + DEX

Cohort E: Treatment 1

CC220 1.0mg + DARA + DEX

Cohort E: Treatment 2

CC220 1.1mg + DARA + DEX

Cohort E: Treatment 3

CC220 1.2mg + DARA + DEX

Cohort E: Treatment 4

CC220 1.3mg + DARA + DEX

Cohort E: Treatment 5

CC220 1.6mg + DARA + DEX

Cohort F: Treatment 1

CC220 1.0mg + BORT + DEX

Cohort F: Treatment 2

CC220 1.1mg + BORT + DEX

Cohort F: Treatment 3

CC220 1.3mg + BORT + DEX

Cohort F: Treatment 4

CC220 1.6mg + BORT + DEX

Cohort G: Treatment 1

CC220 1.1mg + CFZ + DEX

Cohort G: Treatment 2

CC220 1.3mg + CFZ + DEX

Cohort G: Treatment 3

CC220 1.6mg + CFZ + DEX

Cohort H1

CC220 + DEX

Cohort H2

CC220 + DEX

Cohort I

CC220 + DEX

Cohort J1: Treatment 1

CC220Vd 1.0mg + NE-ASCT

Cohort J1: Treatment 2

CC220Vd 1.6mg + NE-ASCT

Cohort K: Treatment 1

CC220 1.0mg + DARA + DEX

Cohort K: Treatment 2

CC220 1.3mg + DARA + DEX

Cohort K: Treatment 3

CC220 1.6mg + DARA + DEX

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cohort A: Treatment 1	0
Cohort A: Treatment 2	0
Cohort A: Treatment 3	0
Cohort A: Treatment 4	0
Cohort A: Treatment 5	0
Cohort A: Treatment 6	0
Cohort B: Treatment 1	0
Cohort B: Treatment 2	0
Cohort B: Treatment 3	0
Cohort B: Treatment 4	0
Cohort B: Treatment 5	0
Cohort B: Treatment 6	0
Cohort B: Treatment 7	0
Cohort B: Treatment 8	0
Cohort B: Treatment 9	0
Cohort B: Treatment 10	0
Cohort D: Treatment 1	0
Cohort E: Treatment 1	0
Cohort E: Treatment 2	0
Cohort E: Treatment 3	0
Cohort E: Treatment 4	0
Cohort E: Treatment 5	0
Cohort F: Treatment 1	0
Cohort F: Treatment 2	0
Cohort F: Treatment 3	0
Cohort F: Treatment 4	0
Cohort G: Treatment 1	0
Cohort G: Treatment 2	0
Cohort G: Treatment 3	0
Cohort H1	0
Cohort H2	0
Cohort I	0
Cohort J1: Treatment 1	1
Cohort J1: Treatment 2	17
Cohort K: Treatment 1	25
Cohort K: Treatment 2	25
Cohort K: Treatment 3	25

Reported measurements

Source class 1

Values in Percentage of Participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Cohort J1: Treatment 1	100.0	Not reported	2.5	100.0	Not reported
Cohort J1: Treatment 2	82.4	Not reported	56.6	96.2	Not reported
Cohort K: Treatment 1	72.0	Not reported	50.6	87.9	Not reported
Cohort K: Treatment 2	100.00	Not reported	86.3	100.0	Not reported
Cohort K: Treatment 3	88.0	Not reported	68.8	97.5	Not reported

Complete source fields

classes

categories
measurements
group Id
OG032
lower Limit
2.5
upper Limit
100.0
value
100.0
group Id
OG033
lower Limit
56.6
upper Limit
96.2
value
82.4
group Id
OG034
lower Limit
50.6
upper Limit
87.9
value
72.0
group Id
OG035
lower Limit
86.3
upper Limit
100.0
value
100.00
group Id
OG036
lower Limit
68.8
upper Limit
97.5
value
88.0

denoms

counts
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
group Id
OG007
value
0
group Id
OG008
value
0
group Id
OG009
value
0
group Id
OG010
value
0
group Id
OG011
value
0
units
Participants

description

dispersion Type

95% Confidence Interval

groups

description
CC220 0.30mg
id
OG000
title
Cohort A: Treatment 1
description
CC220 0.45mg
id
OG001
title
Cohort A: Treatment 2
description
CC220 0.60mg
id
OG002
title
Cohort A: Treatment 3
description
CC220 0.75mg
id
OG003
title
Cohort A: Treatment 4
description
CC220 0.90mg
id
OG004
title
Cohort A: Treatment 5
description
CC220 1.0mg
id
OG005
title
Cohort A: Treatment 6
description
CC220 0.30mg + DEX
id
OG006
title
Cohort B: Treatment 1
description
CC220 0.45mg + DEX
id
OG007
title
Cohort B: Treatment 2
description
CC220 0.60mg + DEX
id
OG008
title
Cohort B: Treatment 3
description
CC220 0.75mg + DEX
id
OG009
title
Cohort B: Treatment 4
description
CC220 0.90mg + DEX
id
OG010
title
Cohort B: Treatment 5
description
CC220 1.0mg + DEX
id
OG011
title
Cohort B: Treatment 6

param Type

NUMBER

population Description

Safety Population in Cohort J1 and Cohort K

reporting Status

POSTED

time Frame

On Average of (Cohort J: 86.21, Cohort K: 56.29) Weeks

title

Very Good Partial Response Rate (ORR) in Cohort J1 and Cohort K

type

SECONDARY

unit Of Measure

Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice